Clipping the wings of glioblastoma: Modulation of WNT as novel therapeutic strategy

Journal of Neuropathology and Experimental Neurology

Volumn 75, Issue 5, 2016, Pages 388-396

  Suwala, Abigail K ^a   Hanaford, Allison ^b   Kahlert, Ulf D ^a   MacIaczyk, Jaroslaw ^a  

^a Institute of Pathology   (Germany)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Glioma; Inhibitors; Noncanonical WNT signaling; Prognostic markers; Small molecules; WNT

Indexed keywords

7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; ACETYLSALICYLIC ACID; ENZASTAURIN; LITHIUM CHLORIDE; N BENZYL 1,2,3,4,8,9 HEXAHYDRO 6 (4 HYDROXYBENZYL) 8 (1 NAPHTHYLMETHYL) 4,7 DIOXO 2H PYRAZINO[1,2 A]PYRIMIDINE 1(6H) CARBOXAMIDE; PROTEIN; WNT PROTEIN; ANTINEOPLASTIC AGENT;

CANCER PROGNOSIS; DISEASE COURSE; GLIOBLASTOMA; HUMAN; MEDICAL DECISION MAKING; MEDULLOBLASTOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY; ANIMAL; BRAIN NEOPLASMS; CANCER STEM CELL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; NEOPLASTIC STEM CELLS; WNT SIGNALING PATHWAY;

EID: 84982170236     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1093/jnen/nlw013     Document Type: Review

References (128)

1. Sacko A, Hou M-M, Temgoua M, et al. Evolution of the Karnosky performance status throughout life in glioblastoma patients. J Neurooncol 2015;122:5671
2. Nava F, Tramacere I, Fittipaldo A, et al. Survival effect of first-and second-line treatments for patients with primary glioblastoma: A cohort study from a prospective registry, 1997-2010. Neuro Oncol 2014;16: 719-27
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
4. Hamza MA, Mandel JJ, Conrad CA, et al. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol 2014;119:135-40
5. Schonberg DL, Lubelski D, Miller TE, et al. Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med 2014;39:82-101
6. Rheinbay E, Suva ML, Gillespie SM, et al. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep 2013;3:1567-79
7. Saito N, Aoki K, Hirai N, et al. Effect of Notch expression in glioma stem cells on therapeutic response to chemo-radiotherapy in recurrent glioblastoma. Brain Tumor Pathol 2015;32:176-83
8. Takezaki T, Hide T, Takanaga H, et al. Essential role of the Hedgehog signaling pathway in human glioma-initiating cells. Cancer Sci 2011;102: 1306-12
9. Qiang L, Yang Y, Ma Y-J, et al. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett 2009;279: 13-21
10. Dai L, Liu Y, He J, et al. Differential profiling studies of N-linked glycoproteins in glioblastoma cancer stem cells upon treatment with csecretase inhibitor. Proteomics 2011;11:4021-8
11. Ding D, Lim KS, Eberhart CG. Arsenic trioxide inhibits Hedgehog, Notch and stem cell properties in glioblastoma neurospheres. Acta Neuropathol Commun 2014;2:31
12. Clevers H, Loh KM, Nusse R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 2014;346:1248012
13. KühlM, Sheldahl LC, Park M, et al. The Wnt/Ca2 pathway: A new vertebrate Wnt signaling pathway takes shape. Trends Genet 2000;16: 279-83
14. Nüsslein-Volhard C. Determination of the embryonic axes of Drosophila. Dev Camb Engl Suppl 1991;1:1-10
15. Jauliac S, López-Rodriguez C, Shaw LM, et al. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 2002;4:540-4
16. Grumolato L, Liu G, Mong P, et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev 2010;24:2517-30
17. Liu F, Millar SE. Wnt/beta-catenin signaling in oral tissue development and disease. J Dent Res 2010;89:318-30
18. Siar CH, Nagatsuka H, Han PP, et al. Differential expression of canonical and non-canonical Wnt ligands in ameloblastoma. J Oral Pathol Med 2012;41:332-9
19. Anne SL, Govek E-E, Ayrault O, et al. WNT3 inhibits cerebellar granule neuron progenitor proliferation and medulloblastoma formation via MAPK activation. PLoS One 2013;8:e81769
20. Yoshioka S, King ML, Ran S, et al. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/b-catenin pathway. Mol Cancer Res 2012;10:469-82
21. Van Amerongen R, Mikels A, Nusse R. Alternative WNT signaling is initiated by distinct receptors. Sci Signal 2008;1:re9
22. Ring L, Neth P, Weber C, et al. b-Catenin-dependent pathway activation by both promiscuous "canonical" WNT3a-, and specific "noncanonical" WNT4-and WNT5a-FZD receptor combinations with strong differences in LRP5 and LRP6 dependency. Cell Signal 2014;26:260-7
23. Jin X, Jeon H-Y, Joo KM, et al. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res 2011;71:3066-75
24. Habu M, Koyama H, Kishida M, et al. Ryk is essential for Wnt-5adependent invasiveness in human glioma. J Biochem 2014;156:29-38
25. Kamino M, Kishida M, Kibe T, et al. Wnt-5a signaling is correlated with infiltrative activity in human glioma by inducing cellular migration and MMP-2. Cancer Sci 2011;102:540-8
26. Schüle R, Dictus C, Campos B, et al. Potential canonical wnt pathway activation in high-grade astrocytomas. Sci World J 2012;2012: 697313
27. Sandberg CJ, Altschuler G, Jeong J, et al. Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt-signaling and a fingerprint associated with clinical outcome. Exp Cell Res 2013;319:2230-43
28. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401
29. Kaur N, Chettiar S, Rathod S, et al. Wnt3a mediated activation of Wnt/ b-catenin signaling promotes tumor progression in glioblastoma. Mol Cell Neurosci 2013;54:44-57
30. Hu G, Wei Y, Kang Y. The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res 2009;15:5615-20
31. Kim Y, Kim KH, Lee J, et al. Wnt activation is implicated in glioblastoma radioresistance. Lab Invest 2012;92:466-73
32. Riganti C, Salaroglio IC, Caldera V, et al. Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/b-catenin pathway. Neuro Oncol 2013;15:1502-17
33. Bo H, Zhang S, Gao L, et al. Upregulation of Wnt5a promotes epithelialto-mesenchymal transition and metastasis of pancreatic cancer cells. BMC Cancer 2013;13:496
34. Boyer B, Vallés AM, Edme N. Induction and regulation of epithelialmesenchymal transitions. Biochem Pharmacol 2000;60:1091-9
35. Hotz B, Arndt M, Dullat S, et al. Epithelial to mesenchymal transition: Expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res 2007;13:4769-76
36. Kahlert UD, Maciaczyk D, Doostkam S, et al. Activation of canonical WNT/b-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-tomesenchymal transition. Cancer Lett 2012;325:42-53
37. Wang Z, Zhang S, Siu TL, et al. Glioblastoma multiforme formation and EMT: Role of FoxM1 transcription factor. Curr Pharm Des 2015; 21:1268-71
38. Mahabir R, Tanino M, Elmansuri A, et al. Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma. Neuro Oncol 2014;16:671-85
39. Birchmeier C, Birchmeier W, Brand-Saberi B. Epithelial-mesenchymal transitions in cancer progression. Acta Anat 1996;156:217-26
40. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat 1995;154:8-20
41. Kahlert UD, Suwala AK, Raabe EH, et al. ZEB1 promotes invasion in human fetal neural stem cells and hypoxic glioma neurospheres. Brain Pathol 2015;25:724-32
42. Mazumdar J, O'Brien WT, Johnson RS, et al. O2 regulates stem cells through Wnt/b-catenin signalling. Nat Cell Biol 2010;12:1007-13
43. Rampazzo E, Persano L, Pistollato F, et al. Wnt activation promotes neuronal differentiation of glioblastoma. Cell Death Dis 2013;4:e500
44. Dejmek J, Dejmek A, Säfholm A, et al. Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res 2005;65:9142-6
45. Kremenevskaja N, von Wasielewski R, Rao AS, et al. Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 2005;1: 2144-54
46. Kurayoshi M, Oue N, Yamamoto H, et al. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 2006;66:10439-48
47. Florian MC, Nattamai KJ, Dörr K, et al. A canonical to non-canonical Wnt signalling switch in haematopoietic stem-cell ageing. Nature 2013; 503:392-6
48. Topol L, Jiang X, Choi H, et al. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol 2003;162:899-908
49. Yuan Y, Niu CC, Deng G, et al. The Wnt5a/Ror2 noncanonical signaling pathway inhibits canonical Wnt signaling in K562 cells. Int J Mol Med 2011;27:63-9
50. Cherry EM, Lee DW, Jung J-U, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-jB-inducing kinase (NIK) and noncanonical NF-jB signaling. Mol Cancer 2015;14:9
51. Augustin I, Goidts V, Bongers A, et al. The Wnt secretion protein Evi/ Gpr177 promotes glioma tumourigenesis. EMBO Mol Med 2012;4: 38-51
52. Tchoghandjian A, Jennewein C, Eckhardt I, et al. Identification of noncanonical NF-jB signaling as a critical mediator of Smac mimeticstimulated migration and invasion of glioblastoma cells. Cell Death Dis 2013;4:e564
53. Yu JM, Jun ES, Jung JS, et al. Role of Wnt5a in the proliferation of human glioblastoma cells. Cancer Lett 2007;257:172-81
54. Schiffman JD, Hodgson JG, VandenBerg SR, et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 2010;70:512-9
55. Hara K, Kageji T, Mizobuchi Y, et al. Blocking of the interaction between Wnt proteins and their co-receptors contributes to the anti-tumor effects of adenovirus-mediated DKK3 in glioblastoma. Cancer Lett 2015;356:496-505
56. Pulvirenti T, Van Der Heijden M, Droms LA, et al. Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas. Cancer Res 2011;71:7280-90
57. Dahmen RP, Koch A, Denkhaus D, et al. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 2001;61:7039-43
58. Eberhart CG, Tihan T, Burger PC. Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000;59: 333-7
59. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67
60. Huang H, Mahler-Araujo BM, Sankila A, et al. APC mutations in sporadic medulloblastomas. Am J Pathol 2000;156:433-7
61. Ellison DW, Onilude OE, Lindsey JC, et al. Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005;23:7951-7
62. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006;7:813-20
63. Götze S, Wolter M, Reifenberger G, et al. Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int J Cancer 2010;126:2584-93
64. Yang Z, Wang Y, Fang J, et al. Downregulation of WIF-1 by hypermethylation in astrocytomas. Acta Biochim Biophys Sin 2010;42:418-25
65. Lambiv WL, Vassallo I, Delorenzi M, et al. The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol 2011;131: 47
66. Wu J, Fang J, Yang Z, et al. Wnt inhibitory factor-1 regulates glioblastoma cell cycle and proliferation. J Clin Neurosci 2012;19:1428-32
67. Vassallo I, Zinn P, Lai M, et al. WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1. Oncogene 2016;35:12-21
68. Foltz G, Yoon J-G, Lee H, et al. Epigenetic regulation of wnt pathway antagonists in human glioblastoma multiforme. Genes Cancer 2010;1: 81-90
69. Morris LGT, Kaufman AM, Gong Y, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet 2013;45:253-61
70. El Kharroubi A, Piras G, Stewart CL. DNA demethylation reactivates a subset of imprinted genes in uniparental mouse embryonic fibroblasts. J Biol Chem 2001;276:8674-80
71. Jiang X, Yu Y, Yang HW, et al. The imprinted gene PEG3 inhibits Wnt signaling and regulates glioma growth. J Biol Chem 2010;285:8472-80
72. Zhang N, Wei P, Gong A, et al. FoxM1 promotes b-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011;20:427-42
73. Gong A-H, Wei P, Zhang S, et al. FoxM1 drives a feed-forward STAT3 activation loop that promotes self-renewal and tumorigenicity of glioblastoma stem-like cells. Cancer Res 2015;75:2337-48
74. Nitta RT, Gholamin S, Feroze AH, et al. Casein kinase 2a regulates glioblastoma brain tumor-initiating cell growth through the b-catenin pathway. Oncogene 2015;34:3688-99
75. Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110
76. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-73
77. Chen L, Huang K, Han L, et al. b-catenin/TCF-4 complex transcriptionally regulates AKT1 in glioma. Int J Oncol 2011;39:883-90
78. Kahlert UD, Suwala AK, Koch K, et al. Pharmacologic Wnt inhibition reduces proliferation, survival, and clonogenicity of glioblastoma cells. J Neuropathol Exp Neurol 2015;74:889-900
79. Liu C, Tu Y, Sun X, et al. Wnt/beta-Catenin pathway in human glioma: Expression pattern and clinical/prognostic correlations. Clin Exp Med 2011;11:105-12
80. Rossi M, Magnoni L, Miracco C, et al. b-catenin and Gli1 are prognostic markers in glioblastoma. Cancer Biol Ther 2011;11:753-61
81. Wu W, Tian Y, Wan H, et al. The expressions of Wnt/b-catenin pathway-related components in brainstem gliomas. Can J Neurol Sci 2013; 40:355-60
82. Shen F, Zhang Y, Yao Y, et al. Proteomic analysis of cerebrospinal fluid: Toward the identification of biomarkers for gliomas. Neurosurg Rev 2014;37:367-80
83. Grigson ER, Ozerova M, Pisklakova A, et al. Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner. PLoS One 2015;10:e0117693
84. Jang G-B, Hong I-S, Kim R-J, et al. Wnt/b-catenin small molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells. Cancer Res 2015;75:1691-702
85. Mallinger A, Crumpler S, Pichowicz M, et al. Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. J Med Chem 2015;58:1717-35
86. Jiang X, Hao H-X, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 2013;110:12649-54
87. Liu J, Pan S, Hsieh MH, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A 2013; 110:20224-9
88. De Robertis A, Mennillo F, Rossi M, et al. Human sarcoma growth is sensitive to small-molecule mediated AXIN stabilization. PLoS One 2014;9:e97847
89. Nencini A, Pratelli C, Quinn JM, et al. Structure-activity relationship and properties optimization of a series of quinazoline-2, 4-diones as inhibitors of the canonical Wnt pathway. Eur JMed Chem 2015;95:526-45
90. Chen B, Dodge ME, Tang W, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-7
91. Huang S-MA, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461:614-20
92. Gunaydin H, Gu Y, Huang X. Novel binding mode of a potent and selective tankyrase inhibitor. PLoS One 2012;7:e33740
93. De Robertis A, Valensin S, Rossi M, et al. Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells. Mol Cancer Ther 2013;12:1180-9
94. Friedberg JW, Mahadevan D, Cebula E, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B-and T-cell non-Hodgkin lymphomas. J Clin Oncol 2014;32:44-50
95. Lee P-Y, Chen C-L, Lin Z-Z, et al. The Aurora kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme. Oncology 2013; 84:326-35
96. Van Brocklyn JR, Wojton J, Meisen WH, et al. Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. Cancer Res 2014;74:5364-70
97. Xia Z, Wei P, Zhang H, et al. AURKA governs self-renewal capacity in glioma-initiating cells via stabilization/activation of b-catenin/Wnt signaling. Mol Cancer Res 2013;11:1101-11
98. Emami KH, Nguyen C, Ma H, et al. A small molecule inhibitor of betacatenin/ CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A 2004;101:12682-7
99. Sukhdeo K, Mani M, Zhang Y, et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A 2007;104:7516-21
100. Huang SC, Clarke DC, Gosline SJC, et al. Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling. PLoS Comput Biol 2013;9:e1002887
101. Dihlmann S, Siermann A, von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate betacatenin/ TCF-4 signaling. Oncogene 2001;20:645-53
102. Dihlmann S, Klein S, Doeberitz Mv Mv. Reduction of beta-catenin/Tcell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated beta-catenin. Mol Cancer Ther 2003;2:509-16
103. Lan F, Yue X, Han L, et al. Antitumor effect of aspirin in glioblastoma cells by modulation of b-catenin/T-cell factor-mediated transcriptional activity. J Neurosurg 2011;115:780-8
104. Handeli S, Simon JA. A small-molecule inhibitor of TCF/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther 2008;7:521-9
105. Shi Z, Qian X, Li L, et al. Nuclear translocation of b-catenin is essential for glioma cell survival. J Neuroimmune Pharmacol 2012;7:892-903
106. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbetaselective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65: 7462-9
107. Kreisl TN, Kim L, Moore K, et al. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res 2009;15:3617-23
108. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28:1168-74
109. Butowski N, Chang SM, Lamborn KR, et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol 2011;13:1331-8
110. Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol 2007;61:153-61
111. Shi Z-D, Qian X-M, Zhang J-X, et al. BASI, a potent small molecular inhibitor, inhibits glioblastoma progression by targeting microRNAmediated b-catenin signaling. CNS Neurosci Ther 2014;20:830-9
112. Atkins RJ, Dimou J, Paradiso L, et al. Regulation of glycogen synthase kinase-3 beta (GSK-3b) by the Akt pathway in gliomas. J Clin Neurosci 2012;19:1558-63
113. Chou C-H, Chou A-K, Lin C-C, et al. GSK3b regulates Bcl2L12 and Bcl2L12A anti-apoptosis signaling in glioblastoma and is inhibited by LiCl. Cell Cycle 2012;11:532-42
114. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013;13:11-26
115. Kim J-A, Choi H-K, Kim T-M, et al. Regulation of mesenchymal stromal cells through fine tuning of canonical Wnt signaling. Stem Cell Res 2015;14:356-68
116. Tamura M, Uyama M, Sugiyama Y, et al. Canonical Wnt signaling activates miR-34 expression during osteoblastic differentiation. Mol Med Rep 2013;8:1807-11
117. Wang L, Liu Y, Li S, et al. Wnt signaling pathway participates in valproic acid-induced neuronal differentiation of neural stem cells. Int J Clin Exp Pathol 2015;8:578-85
118. Tzeng H-E, Yang L, Chen K, et al. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: Resistance reversal with WNT inhibitor. Oncotarget 2015;6:11061-73
119. Shimobayashi M, Hall MN. Making new contacts: The mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 2014;15: 155-62
120. Collu GM, Hidalgo-Sastre A, Brennan K. Wnt-Notch signalling crosstalk in development and disease. Cell Mol Life Sci 2014;71:3553-67
121. Paul I, Bhattacharya S, Chatterjee A, et al. Current understanding on EGFR and Wnt/b-catenin signaling in glioma and their possible crosstalk. Genes Cancer 2013;4:427-46
122. Seelig A, Gottschlich R, Devant RM. A method to determine the ability of drugs to diffuse through the blood-brain barrier. Proc Natl Acad Sci U S A 1994;91:68-72
123. Liu H-L, Hua M-Y, Chen P-Y, et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 2010;255:415-25
124. Lu C, Wang X, Zhu H, et al. Over-expression of ROR2 and Wnt5a cooperatively correlates with unfavorable prognosis in patients with nonsmall cell lung cancer. Oncotarget 2015;6:24912-21
125. Janovska P, Poppova L, Plevova K, et al. Autocrine signaling by Wnt-5a deregulates chemotaxis of leukemic cells and predicts clinical outcome in chronic lymphocytic leukemia. Clin Cancer Res 2016;22: 459-69
126. Qin L, Yin Y-T, Zheng F-J, et al. WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis. Oncotarget 2015;6:10239-52
127. Lin L, Liu Y, Zhao W, et al. Wnt5A expression is associated with the tumor metastasis and clinical survival in cervical cancer. Int J Clin Exp Pathol 2014;7:6072-8
128. Bordonaro M, Tewari S, Cicco CE, et al. A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells. PLoS One 2011;6:e27308